Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

被引：0
|
作者：
Lori J. Goldstein
Raymond P. Perez
Denise Yardley
Linda K. Han
James M. Reuben
Hui Gao
Susan McCanna
Beth Butler
Pier Adelchi Ruffini
Yi Liu
Roberto R. Rosato
Jenny C. Chang
机构：
[1] The Hospital of Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Kansas Medical Research Center,Department of Hematopathology–Research
[3] Current address: Early Oncology Development,undefined
[4] Bristol-Myers Squibb,undefined
[5] Tennessee Oncology,undefined
[6] Indiana University Simon Cancer Center,undefined
[7] Current address: Parkview Cancer Institute,undefined
[8] MD Anderson Cancer Center,undefined
[9] Research and Development,undefined
[10] Dompé farmaceutici S.p.A.,undefined
[11] The Methodist Hospital Research Institute,undefined
[12] Sarah Cannon Research Institute,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [1] A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
    Goldstein, Lori J.
    Perez, Raymond P.
    Yardley, Denise
    Han, Linda K.
    Reuben, James M.
    Gao, Hui
    McCanna, Susan
    Butler, Beth
    Ruffini, Pier Adelchi
    Liu, Yi
    Rosato, Roberto R.
    Chang, Jenny C.
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [2] Reparixin, a CXCR1/2 inhibitor in islet allotransplantation
    Pawlick, Rena L.
    Wink, John
    Pepper, Andrew R.
    Bruni, Antonio
    Abualhassen, Nasser
    Rafiei, Yasmin
    Gala-Lopez, Boris
    Bral, Mariusz
    Shapiro, A. M. James
    ISLETS, 2016, 8 (05) : 115 - 124
  • [3] A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - First analysis
    Schott, Anne F.
    Wicha, Max S.
    Perez, Raymond P.
    Kato, Giraldo
    Avery, Tiffany
    Cristofanilli, Massimo
    Reuben, James M.
    Alpaugh, R. Katherine
    McCanna, Susan
    Ruffini, Pier Adelchi
    Goldstein, Lori J.
    CANCER RESEARCH, 2015, 75
  • [4] 18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial
    Quintela-Fandino, Miguel
    Lluch, Ana
    Manso, Luis
    Calvo, Isabel
    Cortes, Javier
    Angel Garcia-Saenz, Jose
    Gil-Gil, Miguel
    Martinez-Janez, Noelia
    Gonzalez-Martin, Antonio
    Adrover, Encarna
    de Andres, Raquel
    Vinas, Gemma
    Llombart-Cussac, Antonio
    Alba, Emilio
    Guerra, Juan
    Bermejo, Begona
    Zamora, Esther
    Moreno-Anton, Fernando
    Pernas Simon, Sonia
    Carrato, Alfredo
    Lopez-Alonso, Antonio
    Jose Escudero, Maria
    Campo, Ruth
    Carrasco, Eva
    Palacios, Jose
    Mulero, Francisca
    Colomer, Ramon
    CLINICAL CANCER RESEARCH, 2017, 23 (06) : 1432 - 1441
  • [5] Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
    Sirwan Hadad
    Takayuki Iwamoto
    Lee Jordan
    Colin Purdie
    Susan Bray
    Lee Baker
    Gera Jellema
    Steve Deharo
    D. Grahame Hardie
    Lajos Pusztai
    Stacy Moulder-Thompson
    John A. Dewar
    Alastair M. Thompson
    Breast Cancer Research and Treatment, 2011, 128 : 783 - 794
  • [6] Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial
    Hadad, Sirwan
    Iwamoto, Takayuki
    Jordan, Lee
    Purdie, Colin
    Bray, Susan
    Baker, Lee
    Jellema, Gera
    Deharo, Steve
    Hardie, D. Grahame
    Pusztai, Lajos
    Moulder-Thompson, Stacy
    Dewar, John A.
    Thompson, Alastair M.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (03) : 783 - 794
  • [7] The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice
    Verachi, Paola
    Gobbo, Francesca
    Martelli, Fabrizio
    Martinelli, Andrea
    Sarli, Giuseppe
    Dunbar, Andrew
    Levine, Ross L.
    Hoffman, Ronald
    Massucci, Maria Teresa
    Brandolini, Laura
    Giorgio, Cristina
    Allegretti, Marcello
    Migliaccio, Anna Rita
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer
    Schott, Anne F.
    Goldstein, Lori J.
    Cristofanilli, Massimo
    Ruffini, Pier Adelchi
    McCanna, Susan
    Reuben, James M.
    Perez, Raymond P.
    Kato, Giraldo
    Wicha, Max
    CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5358 - 5365
  • [9] Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
    Vidal, Maria
    Falato, Claudette
    Pascual, Tomas
    Sanchez-Bayona, Rodrigo
    Munoz-Mateu, Montserrat
    Cebrecos, Isaac
    Gonzalez-Farre, Xavier
    Cortadellas, Tomas
    Vila, Mireia Margeli
    Luna, Miguel A.
    Siso, Christian
    Amillano, Kepa
    Galvan, Patricia
    Bergamino, Milana A.
    Ferrero-Cafiero, Juan M.
    Salvador, Fernando
    Espinosa Guerrero, Alejandra
    Pare, Laia
    Sanfeliu, Esther
    Prat, Aleix
    Bellet, Meritxell
    CLINICAL CANCER RESEARCH, 2025, 31 (07) : 1223 - 1232
  • [10] Reparixin, CXCR1/2 inhibitor in combination with CDK4/6 inhibitors attenuates endocrine resistant breast cancer growth and metastasis
    Pandithar, Sneha
    Reff, Olivia
    Jin, Kideok
    CANCER RESEARCH, 2022, 82 (12)
12345